Equillium, Inc.
corporate_fare Company Profile
Equillium, Inc. (NASDAQ:EQ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for EQ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for EQ spans 8-K, 10-Q, 4, 144.
Recent high-impact activity:
- Equillium Beats Q3 Estimates, Cash Runway Extended Into 2029
- Equillium Closes $20M Milestone Tranche After First EQ504 Patient Dosed
- First Patient Dosed in EQ504 Phase 1, Unlocking $20M Milestone Tranche
- Equillium Secures Clearance to Launch Phase 1 Trial of EQ504, with Dosing Expected by Early November
- Equillium Cleared to Start First-in-Human Trial of EQ504 in Australia
Financial Snapshot
Short Interest & Short Volume
9.52 days to coverFINRA reported short interest of 5,923,382 shares in EQ as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 9.5 days to cover at its recent average daily volume. On November 20, 2026, 16.4% of EQ volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for EQ, detected from its recent SEC filings.
35.1M Shares Registered for Resale · No Proceeds to the Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →